Investigational drug · Phase 3
SD-101 Dermal
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Epidermolysis Bullosa (EB).
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 15, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
4
Any phase or sponsor naming "SD-101 Dermal"
First trial start
2026
Jul 21, 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SD-101 Dermal", any sponsor or status.
Conditions studied
As listed on its trial records.
- Epidermolysis Bullosa (EB)
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "SD-101 Dermal" as an intervention, largest first.
- Efficacy and Safety Study to Evaluate SD-101 in Epidermolysis BullosaPivotal-lookingRecruiting
Paradigm TherapeuticsIndustry
NCT07482787 · 80 participants (planned) · Start Jul 21, 2026 · Primary completion May 17, 2027
Drug: SD-101 Dermal Cream (6%); Vehicle (SD-101 0%) · For: Epidermolysis Bullosa (EB)
Sites: Rancho Santa Margarita, California; Redwood City, California; Philadelphia, Pennsylvania · 4 sites in all
- An Open Label Extension Safety Study to Evaluate SD-101 in Epidermolysis BullosaPivotal-lookingNot yet recruiting
Paradigm TherapeuticsIndustry
NCT07482813 · 80 participants (planned) · Start Nov 15, 2026 · Primary completion Sep 19, 2027
Drug: SD-101 Dermal Cream (6%) · For: Epidermolysis Bullosa (EB)
Scioderm, Inc.Industry
NCT02014376 · 48 participants · Start Jan 6, 2014 · Primary completion Jun 24, 2014
Drug: SD-101 dermal cream (3%); SD-101 Dermal Cream (6%) and 1 more · For: Epidermolysis Bullosa
Sites: Palo Alto, California; Chicago, Illinois; St Louis, Missouri · 7 sites in all
Scioderm, Inc.Industry
NCT02090283 · 42 participants · Start Mar 26, 2014 · Primary completion Sep 14, 2018
Drug: SD-101 dermal cream (6%) · For: Epidermolysis Bullosa
Sites: Palo Alto, California; Chicago, Illinois; St Louis, Missouri · 7 sites in all
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Epidermolysis Bullosa (EB)
- TCP-25Phase 21 trial
Xinnate AB · Epidermolysis Bullosa (EB), Dystrophic Epidermolysis Bullosa, Junctional Epidermolysis Bullosa
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.